Deals
-
AbbVie to buy immune drug developer Landos
Worth about $138 million upfront, the deal is another example of pharma interest in new drugs for inflammatory conditions like Crohn’s.
By Delilah Alvarado • March 25, 2024 -
Novo to acquire heart failure drug in $1B deal for Cardior
Cardior’s therapy is currently in mid-stage testing and, should the deal close, Novo plans to start another Phase 2 trial.
By Ned Pagliarulo • March 25, 2024 -
Trendline
Biotech dealmaking
Acquisitions of biotech companies have picked up in recent quarters, suggesting depressed valuations may be facilitating deal conversations. Read this trendline for a look at the factors impacting M&A.
By BioPharma Dive staff -
Thermo Fisher, Bayer partner to develop companion diagnostics
The companies aim to identify potential patients for Bayer’s precision cancer therapies and increase access to the treatments.
By Nick Paul Taylor • March 21, 2024 -
AstraZeneca joins radiopharmaceutical deals spree with $2.4B buyout of Fusion
The deal hands AstraZeneca a prostate cancer drug that’s designed differently than Novartis’ fast-selling Pluvicto and currently in mid-stage testing.
By Ben Fidler • March 19, 2024 -
BIO changes stance, backs bill to limit China’s role in US biotech
Pressed by lawmakers, the lobbying group is also “taking steps” to end its relationship with WuXi-AppTec, a major contract manufacturer to the biopharmaceutical industry.
By Jonathan Gardner • March 14, 2024 -
AstraZeneca adds another rare disease drug in $800M buyout of startup Amolyt
The deal gives AstraZeneca a prospect in late-stage testing for parathyroidism and bolsters a rare disease portfolio that mainly consists of drugs from Alexion.
By Kristin Jensen • March 14, 2024 -
Boehringer, Sosei Heptares team up in schizophrenia drug deal
Sosei Heptares could receive more than 700 million euros in a deal to develop medicines aimed at the protein GPR52, an emerging drug target in multiple neurological diseases.
By Delilah Alvarado • March 11, 2024 -
Gilead bets on ‘trispecifics’ in latest cancer drug deal
A small partnership with Merus adds to Gilead’s string of cancer dealmaking, which, so far, has not paid off for the large biotech.
By Jacob Bell • March 6, 2024 -
Abingworth invests in Trodelvy development in deal with Gilead
One of the investment firm’s startups will work with Gilead to expand the cancer drug’s label under the unusual arrangement, with Abingworth receiving payment if successful.
By Kristin Jensen • Feb. 29, 2024 -
NGM to go private through deal with investment firm
The deal would mark a retreat from public markets for the once notable biotech, which was forced to cut staff last year to save cash after trial setbacks.
By Jacob Bell • Feb. 26, 2024 -
AbbVie’s Cerevel deal hits an uncommon roadblock
A “second request” from the Federal Trade Commission could protract the timing of AbbVie’s proposed acquisition, which is slated to close around the middle of the year.
By Jacob Bell • Feb. 20, 2024 -
BioAge raises $170M to back Phase 2-ready obesity drug
BioAge’s Series D will fund a study combining its medicine with Eli Lilly’s Zepbound, a strategy the company hopes could help people lose weight while maintaining muscle mass.
By Jonathan Gardner • Feb. 13, 2024 -
Gilead to buy CymaBay in $4.3B deal for liver disease drug
The proposed acquisition is a bet on CymaBay’s drug seladelpar, which is now under FDA review in a chronic liver disease called primary biliary cholangitis.
By Ned Pagliarulo • Feb. 12, 2024 -
BridgeBio sells partial rights to dwarfism drug for $100M
The deal hands Kyowa Kirin rights in Japan to the drug, which is emerging as a potential rival to BioMarin’s marketed medicine Voxzogo.
By Delilah Alvarado • Feb. 7, 2024 -
AstraZeneca to invest $300M in US cell therapy plant
The UK drugmaker is adding a facility in Rockville, Maryland, after a spate of dealmaking in the therapeutic field.
By Kristin Jensen • Feb. 7, 2024 -
MorphoSys to sell to Novartis for $2.9B, offload cancer drug to Incyte
The deals would hand Novartis a myelofibrosis drug with uncertain regulatory prospects and Incyte a marketed lymphoma medicine that hasn’t sold well.
By Ben Fidler • Feb. 6, 2024 -
Obesity drugs
Novo Holdings to buy contract drugmaker Catalent for $16.5B
In a related deal, Novo Holdings subsidiary Novo Nordisk will buy three major Catalent factories for $11 billion as it works to keep pace with demand for its obesity and diabetes medicines.
By Jonathan Gardner • Feb. 5, 2024 -
Valneva sells regulatory ‘fast pass’ for $103M
The company said it will invest the sale proceeds into testing of an experimental Lyme disease shot and of Ixchiq, its new chikungunya vaccine.
By Delilah Alvarado • Feb. 5, 2024 -
Takeda pays $300M to license Protagonist drug for blood disorder
The agreement gives Protagonist an experienced partner in Takeda, which should help the former commercialize its polycythemia vera treatment.
By Kristin Jensen • Feb. 1, 2024 -
Roche shuffles early stage pipeline as it joins obesity rush
Roche said it was shelving those drugs in favor of experimental programs to treat obesity that it gained from its takeover of Carmot Therapeutics.
By Jonathan Gardner • Feb. 1, 2024 -
Avrobio’s road ends in reverse merger with Tim Springer-backed startup
The gene therapy developer’s demise has given Tectonic Therapeutic, a GPCR-focused startup founded by the prolific biotech entrepreneur, an alternate path to the public markets.
By Kristin Jensen • Jan. 31, 2024 -
Gilead deepens investment in Arcus and TIGIT drugs
The companies said the deal shows their “continued conviction in the TIGIT pathway,” an area of research that so far has not lived up to expectations.
By Jonathan Gardner • Jan. 30, 2024 -
RayzeBio drew other pharma interest before Bristol Myers deal
Two “global biopharmaceutical companies” made bids to buy the radiopharma specialist, but lost out to Bristol Myers, which negotiated aggressively to secure a $4.1 billion buyout.
By Ned Pagliarulo • Jan. 25, 2024 -
Novo strikes another obesity drug deal
The partnership with startup EraCal Therapeutics, a spinout of Harvard University and Zurich University, adds another prospect to Novo’s pipeline of weight loss drugs.
By Kristin Jensen • Jan. 24, 2024 -
Sanofi to buy Inhibrx in deal worth up to $2.2B
The acquisition will give Sanofi an experimental drug for alpha-1 antitrypsin deficiency, while the rest of Inhibrx's assets will be spun into a new company.
By Ned Pagliarulo • Jan. 23, 2024